Menu Search
Equities

Cue Biopharma Inc

1UC:BER

Cue Biopharma Inc

Actions
  • Price (EUR)3.65
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+1.96%
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 20:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

  • Revenue in USD (TTM)432.23k
  • Net income in USD-51.86m
  • Incorporated2014
  • Employees51.00
  • Location
    Cue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
  • Phone+1 (617) 949-2680
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cuebiopharma.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.